JP Morgan Chase
LYEL icon

JP Morgan Chase’s Lyell Immunopharma LYEL Stock Holding History

JP Morgan Chase’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.1K Buy
4,796
+3,328
+227% +$60.2K ﹤0.01% 6345
2026
Q1 		$28.3K Sell
1,468
-148
-9% -$3.46K ﹤0.01% 6416
2025
Q4 		$49.7K Buy
1,616
+1,126
+230% +$25.2K ﹤0.01% 6228
2025
Q3 		$7.96K Sell
490
-2,879
-85% -$32.9K ﹤0.01% 6698
2025
Q2 		$29.8K Sell
3,369
-6,364
-65% -$58K ﹤0.01% 6078
2025
Q1 		$105K Sell
9,733
-11,930
-55% -$146K ﹤0.01% 5547
2024
Q4 		$277K Buy
21,663
+16,826
+348% +$334K ﹤0.01% 5334
2024
Q3 		$134K Sell
4,837
-20
-0.4% -$588 ﹤0.01% 5584
2024
Q2 		$141K Sell
4,857
-27,874
-85% -$1.33M ﹤0.01% 5349
2024
Q1 		$1.46M Buy
32,731
+24,601
+303% +$1.05M ﹤0.01% 4077
2023
Q4 		$315K Sell
8,130
-4,593
-36% -$165K ﹤0.01% 5077
2023
Q3 		$374K Buy
12,723
+954
+8% +$45.3K ﹤0.01% 4651
2023
Q2 		$748K Sell
11,769
-19,481
-62% -$1.08M ﹤0.01% 4253
2023
Q1 		$1.48M Buy
31,250
+2,643
+9% +$141K ﹤0.01% 3762
2022
Q4 		$1.99M Buy
28,607
+2,607
+10% +$259K ﹤0.01% 3561
2022
Q3 		$3.81M Sell
26,000
-359
-1% -$48.6K ﹤0.01% 2971
2022
Q2 		$3.44M Buy
26,359
+439
+2% +$44.9K ﹤0.01% 3103
2022
Q1 		$2.62M Buy
25,920
+2,702
+12% +$327K ﹤0.01% 3546
2021
Q4 		$3.59M Buy
23,218
+6,114
+36% +$1.36M ﹤0.01% 3334
2021
Q3 		$5.06M Buy
+17,104
New +$5.12M ﹤0.01% 3013

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

JP Morgan Chase's LYEL Position: Q2 2026 in Review

JP Morgan Chase increased its Lyell Immunopharma (LYEL) stake by 227% in Q2 2026, buying an estimated $60.2K and bringing the position to 4,796 shares worth $61.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6345.

JP Morgan Chase first reported a position in LYEL in Q3 2021 and has held it in 20 quarters since. The position peaked at $5.06M in Q3 2021. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • JP Morgan Chase held 4,796 shares of Lyell Immunopharma worth $61.1K as of Q2 2026.
  • JP Morgan Chase bought 3,328 Lyell Immunopharma shares in Q2 2026, an estimated $60.2K.
  • Lyell Immunopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6345 holding.
  • JP Morgan Chase first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Lyell Immunopharma position peaked at $5.06M in Q3 2021.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.